Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Per management, the SuperFlex system represents a significant addition to Revvity’s prenatal screening portfolio by addressing financial and operational barriers associated with in-house testing. The company believes the platform’s accessibility, simplicity and flexible throughput can enable this potentially life-saving testing to be more accessible to women, irrespective of where they receive care.
Likely Trend of RVTY Stock Following the News
Shares of RVTY have gained 1.6% since the announcement on Monday. Year to date, the stock rose 21.8% compared with the industry’s 1.2% growth and the S&P 500’s 12.7% gain.
The launch of SuperFlex is expected to strengthen Revvity’s position in the prenatal screening and reproductive health market. By targeting small and mid-sized laboratories that may not have access to high-throughput centralized testing, the platform could expand the company’s addressable market and support broader adoption of its prenatal screening solutions. Growing demand for preeclampsia screening, along with planned expansion into Asia-Pacific, could create additional opportunities for Revvity to increase instrument placements, consumables demand and recurring revenue over the long term.
RVTY currently has a market capitalization of $12.91 billion.
Image Source: Zacks Investment Research
More on the News
SuperFlex is a fully automated benchtop immunoanalyzer that uses chemiluminescence immunoassay (CLIA) technology and features a cartridge-based design with 24 sample positions. The system can process up to 60 tests per hour, supports continuous sample loading and delivers initial results in as little as 14 minutes. Its flexible workflow allows laboratories to process samples as needed for both urgent and routine testing.
SuperFlex supports in-house screening for preeclampsia, a condition affecting 2% to 8% of pregnancies, while offering first- and second-trimester biochemical prenatal screening. It offers an accessible solution with lower instrument costs, annual maintenance and no reagent wastage at low sample volumes. The system combines full automation with a user-friendly design that can reduce training requirements and integrates with Revvity’s LifeCycle software.
Revvity’s LifeCycle software is a comprehensive informatics and risk-calculation solution that supports maternal and fetal health screening. Together, SuperFlex and LifeCycle provide a decentralized prenatal screening solution for streamlined risk assessment and LIMS data transfer. By enabling cost-effective, decentralized testing, SuperFlex can help laboratories and clinics bring timely prenatal screening closer to patients.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global preeclampsia diagnostics market is predicted to be valued at $1.33 billion in 2026 and is expected to witness a CAGR of 3.1% through 2035.
Factors like the rising awareness of maternal health, technological advancements in point-of-care testing, and increasing prenatal screening initiatives are boosting the market’s growth.
Other News
Revvity recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. The platform is targeted for launch in the second half of 2027.
Revvity recently launched Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research.
Some better-ranked stocks from the broader medical space are Globus MedicalGMED, Cardinal HealthCAH and The Cooper Companies COO.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, reported a fourth-quarter fiscal 2026 adjusted EPS of $2.91, which beat the Zacks Consensus Estimate by 20.3%. Revenues of $63.67 billion missed the Zacks Consensus Estimate by 2.9%.
CAH has an estimated long-term earnings growth rate of 13.5%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.7%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.